A Study of Merestinib (LY2801653) in Healthy Participants
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 5/21/2016 |
| Start Date: | May 2016 |
| End Date: | August 2016 |
| Contact: | This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or |
| Phone: | 1-317-615-4559 |
The Effect of Food on the Bioavailability of Merestinib in Healthy Subjects
The purpose of this study is to evaluate the effect of food on merestinib (standard meal and
high-fat meal) compared to the fasted state. The study will also measure how much of the
study drug gets into the blood stream and how long it takes the body to get rid of it. In
addition, the tolerability of the study drug will be evaluated. Information about any side
effects that may occur will also be collected. The study will last approximately 28 days.
Screening is required within 28 days prior to the start of the study.
high-fat meal) compared to the fasted state. The study will also measure how much of the
study drug gets into the blood stream and how long it takes the body to get rid of it. In
addition, the tolerability of the study drug will be evaluated. Information about any side
effects that may occur will also be collected. The study will last approximately 28 days.
Screening is required within 28 days prior to the start of the study.
Inclusion Criteria:
- Generally healthy sterile male and female participants
- Body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive
- Are willing and able to eat the protocol specified high-fat breakfast
Exclusion Criteria:
- Have consumed grapefruits or grapefruit-containing products, Seville oranges or
Seville orange juice, star fruit, star fruit juice, or star fruit-containing
products, or commercial apple or orange juice within 14 days prior to first dosing
- Regularly use known drugs of abuse and/or show positive findings on urinary drug
screening
- Have donated blood of more than 500 milliliters (mL) within the last month
- Cannot stop taking over-the-counter (OTC) or prescription medications that alter
gastric pH, at least 14 days prior to first dosing
- Have previously completed or withdrawn from this study or any other study
investigating merestinib, and have previously received the investigational product
We found this trial at
1
site
Daytona Beach, Florida 32117
Principal Investigator: Hugh A Coleman
Phone: 386-366-6446
Click here to add this to my saved trials
